Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AVTX Avalo Therapeutics Inc

Post-Mkt 05-22 19:55:14 EDT

16.35

-0.25

-1.51%

盘后16.40

+0.05+0.31%

18:28 EDT

High17.01	Low16.02	Vol1.32M
Open16.60	D1 Closing16.60	Amplitude5.96%
Mkt Cap859.45M	Tradable Cap803.55M	Total Shares52.57M
T/O21.64M	T/O Rate2.68%	Tradable Shares49.15M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AVTX","market":"US","secType":"STK","nameCN":"Avalo Therapeutics Inc","latestPrice":16.35,"timestamp":1779480000000,"preClose":16.6,"halted":0,"volume":1317318,"hourTrading":{"tag":"盘后","latestPrice":16.4,"preClose":16.35,"latestTime":"18:28 EDT","volume":4645,"amount":75950.02339999999,"timestamp":1779488907684,"change":0.05,"changeRate":0.003058,"amplitude":0.006728},"delay":0,"changeRate":-0.01506024096385542,"floatShares":49146600,"shares":52565600,"eps":-5.57,"marketStatus":"Post-Mkt","change":-0.25,"latestTime":"05-22 19:55:14 EDT","open":16.6,"high":17.01,"low":16.02,"amount":21643260.737855997,"amplitude":0.059639,"askPrice":19.01,"askSize":100,"bidPrice":16.04,"bidSize":22,"shortable":3,"etf":0,"ttmEps":-5.57,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1779494400000},"marketStatusCode":4,"adr":0,"listingDate":1447390800000,"exchange":"NASDAQ","adjPreClose":16.6,"preHourTrading":{"tag":"盘前","latestPrice":16.59,"preClose":16.6,"latestTime":"05:59 EDT","volume":2,"amount":33.190002,"timestamp":1779443964596,"change":-0.01,"changeRate":-0.000602,"amplitude":0.000602},"postHourTrading":{"tag":"盘后","latestPrice":16.4,"preClose":16.35,"latestTime":"18:28 EDT","volume":4645,"amount":75950.02339999999,"timestamp":1779488907684,"change":0.05,"changeRate":0.003058,"amplitude":0.006728},"volumeRatio":0.781567,"impliedVol":0.9735,"impliedVolPercentile":0.4622},"requestUrl":"/m/hq/s/AVTX/wiki","defaultTab":"wiki","newsList":[{"id":"2637417863","title":"Avalo Therapeutics grants new hire option for 34,000 shares at $16.6 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2637417863","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637417863?lang=en_us&edition=fundamental","pubTime":"2026-05-23 04:01","pubTimestamp":1779480092,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics granted an inducement stock option covering 34,000 common shares to a new employee on May 21, 2026.The option exercise price was set at $16.6 per share, matching the stock’s closing price on the grant date.Vesting starts with 25% on the first anniversary of the employee’s start date, with the remainder vesting monthly over the next 36 months, subject to continued service.The award was issued under the company’s 2025 Inducement Award Plan.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL9QBY31:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","BK4112","IE00BN0W2W23.USD","NDAQ","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","SG9999014005.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","BK4139","BK4588","BK4585","LU0314104364.USD","SG9999014013.SGD","AVTX","SG9999014039.USD","IE00B64PRP62.GBP","LU2210150020.SGD","IE00BN0W2T93.GBP","LU2095319765.USD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637341222","title":"Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637341222","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637341222?lang=en_us&edition=fundamental","pubTime":"2026-05-23 04:01","pubTimestamp":1779480060,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nTUA7FVY4L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636863864","title":"Avalo CMO Mittie Doyle disposes 3,000 shares for $56,280","url":"https://stock-news.laohu8.com/highlight/detail?id=2636863864","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636863864?lang=en_us&edition=fundamental","pubTime":"2026-05-20 04:11","pubTimestamp":1779221465,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Chief Medical Officer Doyle Mittie sold 3,000 common shares on May 15 at USD 18.76.The sale followed the exercise of 3,000 stock options at USD 12.65 on the same day.Mittie ended the day with 3,622 common shares held directly.Derivative holdings included 128,625 stock options outstanding following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 19, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDLb1BH8Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Avalo CMO Mittie Doyle disposes 3,000 shares for $56,280","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635713219","title":"Avalo Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $35 From $40","url":"https://stock-news.laohu8.com/highlight/detail?id=2635713219","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635713219?lang=en_us&edition=fundamental","pubTime":"2026-05-14 18:14","pubTimestamp":1778753657,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nAZN4SW89M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635358799","title":"U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2635358799","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635358799?lang=en_us&edition=fundamental","pubTime":"2026-05-14 15:24","pubTimestamp":1778743446,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology May 14 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cisc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL4N41R0NP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMP","CLH","CORZ","ARMK","CVNX","BXP","AEE","CIFU","MRVL","AKAM","ARVN","AFRM","CIFG","DLLL","CSR","MVLL","ABBV","CIFR","CVNY","CPT","DECK","ANTX","ASO","AVTX","AMGN","DMRA","ET","AN","CSCL","CVNA","CSCO","CAVA","ASTH","MRVU","DTE","CMS","DELL","APGE","DT","ATLC","CSCS","ANDG","CAKE","CGON","CARR","CMC","AFRU","EBAY","DOCS","AVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635401780","title":"Avalo Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635401780","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635401780?lang=en_us&edition=fundamental","pubTime":"2026-05-13 21:31","pubTimestamp":1778679094,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryAvalo Therapeutics Inc AVTX.OQ reported a quarterly adjusted loss of $1.13 per share for the quarter ended March","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL8N41Q1TA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635786741","title":"Avalo Therapeutics Q1 net loss widens on increased R&D spend","url":"https://stock-news.laohu8.com/highlight/detail?id=2635786741","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635786741?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:12","pubTimestamp":1778670738,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Q1 net loss widens on increased R&D spendOverviewUS biotech firm's Q1 net loss missed analyst expectationsQ1 pretax profit missed analyst estimates, driven by higher R&D and admin e","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL1N41Q0HK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635786202","title":"Earnings Flash (AVTX) Avalo Therapeutics Posts Q1 Loss $0.98 a Share, vs. FactSet Est of $1.03 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2635786202","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635786202?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:08","pubTimestamp":1778670507,"startTime":"0","endTime":"0","summary":"Earnings Flash (AVTX) Avalo Therapeutics Posts Q1 Loss $0.98 a Share, vs. FactSet Est of $1.03 Loss","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635786995","title":"Avalo net loss widens to $19.63 million in Q1 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2635786995","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635786995?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:03","pubTimestamp":1778670208,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics posted a Q1 net loss of USD 19.63 million, widening from a loss of USD 13.15 million a year earlier; loss per share narrowed to USD 0.98 from USD 1.25.Operating loss widened to USD 20.9 million from USD 14.67 million, with research and development expense rising to USD 14.05 million from USD 9.12 million.Cash, cash equivalents, and short-term investments totaled USD 82 million at March 31, 2026; net cash used in operating activities was USD 17.7 million.Completed an underwritten public offering of common stock and pre-funded warrants for gross proceeds of USD 431.3 million, with net proceeds of about USD 405 million; cash runway expected to extend into 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therap","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDLbf27Rd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635866737","title":"Avalo Therapeutics: Current Cash, Cash Equivalents, and Short-Term Investments Expected to Fund Operations Into 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2635866737","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635866737?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:00","pubTimestamp":1778670003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nPLXE98963:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635785025","title":"Avalo Therapeutics Q1 Operating Expenses USD 20.901 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635785025","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635785025?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:00","pubTimestamp":1778670003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nPLXE98963:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635578615","title":"Avalo Therapeutics Q1 EPS USD -0.98","url":"https://stock-news.laohu8.com/highlight/detail?id=2635578615","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635578615?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:00","pubTimestamp":1778670003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nPLXE98963:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635178636","title":"Press Release: Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2635178636","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635178636?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:00","pubTimestamp":1778670000,"startTime":"0","endTime":"0","summary":"moderate to severe hidradenitis suppurativa  and plan to advance into. -- Completed public offering of equity securities for gross proceeds of. -- Cash, cash equivalents, and short-term investments of $82 million as of. March 31, 2026, not including the subsequent financing. WAYNE, Pa., May 13, 2026  -- Avalo Therapeutics, Inc.  , a clinical stage biotechnology company fully dedicated to developing IL-1<BETA>-based treatments for immune-mediated inflammatory diseases, today announced business updates and first quarter 2026 financial results.\"The positive Phase 2 LOTUS trial results of abdakibart in HS, which demonstrated a deep and consistent clinical response across both HiSCR75 and HiSCR50 endpoints, mark the beginning of a transformative period for Avalo,\" said Garry Neil, MD, Chief Executive Officer of Avalo. \"With our recently secured financing, Avalo is well-positioned to advance abdakibart into a registrational phase 3 program. Our focus remains on delivering this innovative mec","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","AVTX","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634403112","title":"U.S. RESEARCH ROUNDUP-Airbnb, HII, Tesla","url":"https://stock-news.laohu8.com/highlight/detail?id=2634403112","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634403112?lang=en_us&edition=fundamental","pubTime":"2026-05-11 15:27","pubTimestamp":1778484476,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Airbnb, HII, Tesla May 11 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Airbnb, HII and Tesla, o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL4N41O0GT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AIZ","BOOT","AMDD","CF","AFRM","AMDL","AMPH","AMYY","ARTV","BP","CPT","AMUU","ASPN","AGL","AMDW","FRDU","ABNY","AVTX","ALBG","TECH","CRBU","CTRI","AIDX","CWH","APO","ARXS","BCAX","ANIP","WHD","AMD","ABNB","ALB","ASTH","CG","BWA","CRC","BBIO","CAR","CPRX","ATLC","BILL","ABNG","CRI","BAM","BDX","BWXT","F","AFRU","AZTA","AVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633682514","title":"Avalo Therapeutics Inc  expected to post a loss of $1.05 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633682514","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633682514?lang=en_us&edition=fundamental","pubTime":"2026-05-08 23:52","pubTimestamp":1778255543,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Inc  expected to post a loss of $1.05 a share - Earnings Preview Avalo Therapeutics Inc AVTX.OQ AVTX.O is expected to  show no change in quarterly revenue when it reports  results o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L1YL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633017129","title":"Avalo CFO Christopher Sullivan disposes of common shares worth $1.03 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633017129","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633017129?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:22","pubTimestamp":1778185325,"startTime":"0","endTime":"0","summary":"Christopher Ryan Sullivan, Chief Financial Officer, reported sale of 47,000 shares of common stock on May 6, 2026, leaving 423 shares owned.Transaction included exercise of 47,000 stock options at USD 8.04, followed by open-market sales at prices ranging from USD 17.95 to USD 22.88.Derivative holdings fell to 116,000 stock options exercisable at USD 8.04, expiring Jan. 28, 2035.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 07, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL3kbW0k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633817145","title":"Avalo CMO Mittie Doyle disposes 108,234 shares worth $2.28 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633817145","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633817145?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:20","pubTimestamp":1778185258,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Chief Medical Officer Mittie Doyle cut direct common stock holdings to 3,622 shares, per a Form 4 filing.Transactions on May 5-6 included option exercises for 108,234 shares at USD 8.04-12.65, followed by sales of 108,234 shares at USD 16-22.88.Report also showed 250,152 stock options held after the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 07, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL5NN2FC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633171494","title":"Avalo Chief Legal Officer Paul Varki disposes of common shares worth $1.49 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633171494","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633171494?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:20","pubTimestamp":1778185232,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Chief Legal Officer Paul Varki reported sales totaling 75,063 common shares on May 6, 2026, cutting direct holdings to 3,634 shares.Transactions also included option exercises for 75,063 shares at prices of USD 13.43, USD 8.04.Sales were executed at prices ranging from USD 18.5 to USD 23.71 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 07, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL4nFdsW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633171547","title":"Avalo Therapeutics director Mitchell Chan sells 3,167 shares for $72,478.96","url":"https://stock-news.laohu8.com/highlight/detail?id=2633171547","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633171547?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:18","pubTimestamp":1778185121,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics director Mitchell Chan sold 3,167 common shares on May 6 at USD 22.88.Direct holdings fell to 3,166 shares following transaction.Sale was executed under Rule 10b5-1 trading plan adopted on Nov. 19, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 07, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL8RyyZ5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Avalo Therapeutics director Mitchell Chan sells 3,167 shares for $72,478.96","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633153110","title":"Guggenheim Keeps Their Buy Rating on Avalo Therapeutics (AVTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633153110","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633153110?lang=en_us&edition=fundamental","pubTime":"2026-05-07 01:56","pubTimestamp":1778090188,"startTime":"0","endTime":"0","summary":"In a report released today, Yatin Suneja from Guggenheim maintained a Buy rating on Avalo Therapeutics, with a price target of $50.00. According to...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-avalo-therapeutics-avtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-avalo-therapeutics-avtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.avalotx.com","stockEarnings":[{"period":"1week","weight":-0.1268},{"period":"1month","weight":0.1617},{"period":"3month","weight":0.1682},{"period":"6month","weight":-0.069},{"period":"1year","weight":3.3799},{"period":"ytd","weight":-0.0859}],"compareEarnings":[{"period":"1week","weight":-0.0073},{"period":"1month","weight":0.0549},{"period":"3month","weight":0.0773},{"period":"6month","weight":0.127},{"period":"1year","weight":0.2743},{"period":"ytd","weight":0.0892}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":-0.063135},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.010519},{"month":3,"riseRate":0.272727,"avgChangeRate":0.280205},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.088879},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.041735},{"month":6,"riseRate":0.7,"avgChangeRate":0.011587},{"month":7,"riseRate":0.5,"avgChangeRate":0.025049},{"month":8,"riseRate":0.6,"avgChangeRate":-0.034606},{"month":9,"riseRate":0.6,"avgChangeRate":0.04604},{"month":10,"riseRate":0.6,"avgChangeRate":0.161359},{"month":11,"riseRate":0.4,"avgChangeRate":-0.050828},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.047903}],"exchange":"NASDAQ","name":"Avalo Therapeutics Inc","nameEN":"Avalo Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Avalo Therapeutics Inc(AVTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Avalo Therapeutics Inc,AVTX,Avalo Therapeutics Inc股票,Avalo Therapeutics Inc股票老虎,Avalo Therapeutics Inc股票老虎国际,Avalo Therapeutics Inc行情,Avalo Therapeutics Inc股票行情,Avalo Therapeutics Inc股价,Avalo Therapeutics Inc股市,Avalo Therapeutics Inc股票价格,Avalo Therapeutics Inc股票交易,Avalo Therapeutics Inc股票购买,Avalo Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Avalo Therapeutics Inc(AVTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}